2014
An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone
Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone. Journal Of Substance Use And Addiction Treatment 2014, 47: 35-40. PMID: 24674234, PMCID: PMC4042403, DOI: 10.1016/j.jsat.2014.02.008.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialXR-NTXGamma-glutamyl transferaseAlanine aminotransferaseMental illnessAspartate aminotransferaseRandomized placebo-controlled trialMonthly injectable formulationXR-NTX armExtended-release naltrexoneHepatic enzyme elevationHepatic enzyme levelsRelease naltrexoneAntiretroviral therapyHCV infectionBaseline characteristicsHepatic transaminasesEnzyme elevationPsychiatric medicationsHepatotoxicity concernsGlutamyl transferaseAlcohol dependenceOpioidsHIVNaltrexone
2011
Public Health Implications for Adequate Transitional Care for HIV-Infected Prisoners: Five Essential Components
Springer SA, Spaulding AC, Meyer JP, Altice FL. Public Health Implications for Adequate Transitional Care for HIV-Infected Prisoners: Five Essential Components. Clinical Infectious Diseases 2011, 53: 469-479. PMID: 21844030, PMCID: PMC3156144, DOI: 10.1093/cid/cir446.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCombination antiretroviral therapyPublic health implicationsTreatment outcomesPoor HIV treatment outcomesHuman immunodeficiency virus (HIV) infectionImmunodeficiency syndrome prevalenceHIV treatment outcomesImmunodeficiency virus infectionHealth implicationsMental illness treatmentSubstance use disordersCase management servicesAntiretroviral therapySecondary preventionSyndrome prevalenceTransitional careImmunological outcomesCriminal justice populationsVirus infectionIllness treatmentUse disordersHIVMental illnessAlcohol useMedical insuranceHIV Treatment in the Criminal Justice System: Critical Knowledge and Intervention Gaps
Meyer JP, Chen NE, Springer SA. HIV Treatment in the Criminal Justice System: Critical Knowledge and Intervention Gaps. AIDS Research And Treatment 2011, 2011: 680617. PMID: 21776379, PMCID: PMC3137962, DOI: 10.1155/2011/680617.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSubstance Abuse, Violence, and HIV in Women: A Literature Review of the Syndemic
Meyer JP, Springer SA, Altice FL. Substance Abuse, Violence, and HIV in Women: A Literature Review of the Syndemic. Journal Of Women's Health 2011, 20: 991-1006. PMID: 21668380, PMCID: PMC3130513, DOI: 10.1089/jwh.2010.2328.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHIV/AIDSSubstance abuseHealthcare utilizationPoor HIV outcomesBetter health outcomesEvidence-based interventionsNegative health consequencesHIV outcomesHIV statusMedication adherenceHealth outcomesMental illnessHealth consequencesMental healthUrban womenWomenHIVBidirectional relationshipVulnerable groupsAIDSPrevention of violenceCurrent findingsAdherenceFuture studiesInconsistent definitions
2010
Neurocognitive Impairment and HIV Risk Factors: A Reciprocal Relationship
Anand P, Springer SA, Copenhaver MM, Altice FL. Neurocognitive Impairment and HIV Risk Factors: A Reciprocal Relationship. AIDS And Behavior 2010, 14: 1213-1226. PMID: 20232242, PMCID: PMC2906682, DOI: 10.1007/s10461-010-9684-1.Peer-Reviewed Original ResearchConceptsRisk reduction interventionsMedication adherenceCognitive impairmentRisk behaviorsHIV risk factorsHIV risk behaviorsImpact of HIVEffectiveness of interventionsSuboptimal adherenceRisk factorsNeurocognitive impairmentMental illnessCognitive functionSubstance abuseImpairmentAdherenceHIVInterventionReciprocal relationshipRiskSignificant barriers